Referências
Principais artigos
World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Sep 2015 [internet publication].Texto completo
US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Feb 2024 [internet publication].Texto completo
World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].Texto completo
Artigos de referência
1. World Health Organization. HIV/AIDS: online QA. Nov 2022 [internet publication].Texto completo
2. Worobey M. The origins and diversifications of HIV. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008.
3. Wilson D, Naidoo S, Bekker LG, et al. Handbook of HIV medicine. South Africa: Oxford University Press; 2002.
4. Robertson DL, Anderson JP, Bradac JL, et al. HIV-1 nomenclature proposal. Science. 2000 Apr 7;288(5463):55-6. Resumo
5. Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2018 Nov 30. pii: S1473-3099(18)30647-9. Resumo
6. Yamaguchi J, McArthur C, Vallari A, et al. Complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):319-22. Resumo
7. Wymant C, Bezemer D, Blanquart F, et al. A highly virulent variant of HIV-1 circulating in the Netherlands. Science. 2022 Feb 4;375(6580):540-5.Texto completo Resumo
8. Gottlieb GS, Raugi DN, Smith RA. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV. 2018 Jul;5(7):e390-9. Resumo
9. Fidler S, Fox J. Primary HIV infection: a medical and public health emergency requiring rapid specialist management. Clin Med (Lond). 2016 Apr;16(2):180-3.Texto completo Resumo
10. Joint United Nations Programme on HIV/AIDS. In danger: UNAIDS global AIDS update 2022. 2022 [internet publication].Texto completo
11. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019 Dec;6(12):e831-9.Texto completo Resumo
12. Li Z, Purcell DW, Sansom SL, et al. Vital signs: HIV transmission along the continuum of care - United States, 2016. MMWR Morb Mortal Wkly Rep. 2019 Mar 22;68(11):267-72.Texto completo Resumo
13. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2021 – 2020 data. Stockholm: ECDC; 2021.Texto completo
14. UK Health Security Agency. HIV testing, PrEP, new HIV diagnoses, and care outcomes for people accessing HIV services: 2023 report. Oct 2023 [internet publication].Texto completo
15. Centers for Disease Control and Prevention. Estimated annual number of HIV infections - United States, 1981-2019. MMWR Morb Mortal Wkly. 2021 Jun 4:70(22);801-6.Texto completo
16. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2017–2021. May 2023 [internet publication].Texto completo
17. Dailey AF, Gant Z, Hu X, et al. Association between social vulnerability and rates of HIV diagnoses among black adults, by selected characteristics and region of residence - United States, 2018. MMWR Morb Mortal Wkly Rep 2022;71:167-70.Texto completo Resumo
18. Lee K, Trujillo L, Olansky E, et al. Factors associated with use of HIV prevention and health care among transgender women - seven urban areas, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022 May 20;71(20):673-9.Texto completo Resumo
19. Nyamweya S, Hegedus A, Jaye A, et al. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol. 2013 Jul;23(4):221-40. Resumo
20. Pope M, Hause AT. Transmission, acute HIV-1 infection and the quest to prevent infection. Nat Med. 2003 Jul;9(7):847-52. Resumo
21. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008 Sep 1;47(5):712-22.Texto completo Resumo
22. Morris L, Cilliers T. Viral structure, replication, tropism, pathogenesis and natural history. In: Abdool Karim SS, Abdool Karim Q, eds. HIV/AIDS in South Africa. Cambridge University Press; 2005:79-89.
23. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Def Syndr Hum Retrovirol. 1995 Oct 1;10(2):175-6. Resumo
24. Artenie A, Stone J, Fraser H, et al. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023 Mar 27;S2468-1253(23)00018-3.Texto completo Resumo
25. Farhadian N, Karami Matin B, Farnia V, et al. The prevalence of people who inject drugs among those with HIV late presentation: a meta-analysis. Subst Abuse Treat Prev Policy. 2022 Feb 10;17(1):11.Texto completo Resumo
26. Arum C, Fraser H, Artenie AA, et al. Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health. 2021 May;6(5):e309-23.Texto completo Resumo
27. Malekinejad M, Barker EK, Merai R, et al. Risk of HIV acquisition among men who have sex with men infected with bacterial sexually transmitted infections: a systematic review and meta-analysis. Sex Transm Dis. 2021 Oct 1;48(10):e138-48.Texto completo Resumo
28. Varghese B, Maher JE, Peterman TA, et al. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis. 2002 Jan;29(1):38-43. Resumo
29. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992 Mar 28;304(6830):809-13.Texto completo Resumo
30. Bell DM. Occupational risk of human immunodeficiency virus infection in health care workers: an overview. Am J Med. 1997 May 19;102(5B):9-15. Resumo
31. Cooper ER, Charurat M, Mofenson L, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94. Resumo
32. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016 Nov 13;30(17):2665-83.Texto completo Resumo
33. Tepper NK, Curtis KM, Cox S, et al. Update to U.S. medical eligibility criteria for contraceptive use, 2016: updated recommendations for the use of contraception among women at high risk for HIV infection. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):405-10.Texto completo Resumo
34. World Health Organization. Contraceptive eligibility for women at high risk of HIV: guidance statement - recommendations on contraceptive methods used by women at high risk of HIV. 2019 [internet publication].Texto completo
35. Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017 Dec;17(12):1303-16.Texto completo Resumo
36. Looker KJ, Welton NJ, Sabin KM, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis. 2020 Feb;20(2):240-9.Texto completo Resumo
37. Marfatia YS, Pandya I, Mehta K. Condoms: Past, present, and future. Indian J Sex Transm Dis AIDS. 2015 Jul-Dec;36(2):133-9.Texto completo Resumo
38. Hanum N, Cambiano V, Sewell J, et al. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study. Lancet Public Health. 2020 Sep;5(9):e501-11.Texto completo Resumo
39. Finlayson T, Cha S, Xia M, et al; National HIV Behavioral Surveillance Study Group. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men - 20 urban areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603.Texto completo Resumo
40. Riddell J 4th, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018 Mar 27;319(12):1261-8. Resumo
41. O Murchu E, Marshall L, Teljeur C, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022 May 11;12(5):e048478.Texto completo Resumo
42. Jourdain H, de Gage SB, Desplas D, et al. Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. Lancet Public Health. 2022 Jun;7(6):e529-36.Texto completo Resumo
43. Sullivan AK, Saunders J, Desai M, et al. HIV pre-exposure prophylaxis and its implementation in the PrEP impact trial in England: a pragmatic health technology assessment. Lancet HIV. 2023 Dec;10(12):e790-806.Texto completo Resumo
44. Delaugerre C, Rodriguez C, Capitant C, et al. Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. AIDS. 2018;32(16):2353-61. Resumo
45. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Sep 2015 [internet publication].Texto completo
46. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update: a clinical practice guideline. Dec 2021 [internet publication].Texto completo
47. American College of Obstetricians and Gynecologists. Practice advisory to committee opinion no. 595: preexposure prophylaxis for the prevention of human immunodeficiency virus. Jun 2022 [internet publication].Texto completo
48. US Preventive Services Task Force. Recommendation: prevention of acquisition of HIV: preexposure prophylaxis. Aug 2023 [internet publication].Texto completo
49. Holt M, Lea T, Mao L, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17. Lancet HIV. 2018 Aug;5(8):e448-56. Resumo
50. Hart TA, Noor SW, Berlin GW, et al. Pre-exposure prophylaxis and bacterial sexually transmitted infections (STIs) among gay and bisexual men. Sex Transm Infect. 2023 May;99(3):167-72.Texto completo Resumo
51. Cohen SE, Sachdev D, Lee SA, et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018 Nov 29 [Epub ahead of print]. Resumo
52. Tumarkin E, Siedner MJ, Bogoch II. The BMJ 10-minute consultation: HIV pre-exposure prophylaxis (PrEP). BMJ. 2019 Jan 17;364:k4681.
53. US Food and Drug Administration. FDA approves first injectable treatment for HIV pre-exposure prevention. Dec 2021 [internet publication].Texto completo
54. Marshall BDL, Goedel WC, King MRF, et al. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. Lancet HIV. 2018 Sep;5(9):e498-505.Texto completo Resumo
55. Landovitz RJ, Hanscom BS, Clement ME, et al. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV. 2023 Dec;10(12):e767-78.Texto completo Resumo
56. World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. Jul 2022 [internet publication].Texto completo
57. Antoni G, Tremblay C, Delaugerre C, et al. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV. 2020 Feb;7(2):e113-20. Resumo
58. Lattré T, Van Holder C. Revisiting the functional severity scale of the Boston carpal tunnel questionnaire, a comment concerning the use of digital communication technology. Muscle Nerve. 2021 Jun;63(6):E57-8.Texto completo Resumo
59. Musekiwa A, Fernando NB, Abariga SA. Effectiveness of vaginal microbicides in preventing HIV transmission. Trop Med Int Health. 2020 Jul;25(7):790-802.Texto completo Resumo
60. Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016 Dec 1;375(22):2133-43.Texto completo Resumo
61. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Jul 2021 [internet publication].Texto completo
62. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168-74.Texto completo Resumo
63. Anglemyer A, Rutherford GW, Horvath T, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009153.Texto completo Resumo
64. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.Texto completo Resumo
65. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016 Jul 12;316(2):171-81.Texto completo Resumo
66. Bavinton BR, Pinto AN, Phanuphak N, et al; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018 Aug;5(8):e438-47. Resumo
67. PARTNER Study Group. HIV transmission risk through condomless sex in gay couples with suppressive ART: the PARTNER2 Study extended results in gay men. 2018 [internet publication].Texto completo
68. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019 Jun 15;393(10189):2428-38.Texto completo Resumo
69. LeMessurier J, Traversy G, Varsaneux O, et al. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review. CMAJ. 2018 Nov 19;190(46):E1350-60.Texto completo Resumo
70. Broyles LN, Luo R, Boeras D, et al. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet. 2023 Aug 5;402(10400):464-71.Texto completo Resumo
71. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Feb 2024 [internet publication].Texto completo
72. Sharma SC, Raison N, Khan S, et al. Male circumcision for the prevention of human immunodeficiency virus (HIV) acquisition: a meta-analysis. BJU Int. 2018 Apr;121(4):515-26.Texto completo Resumo
73. Yuan T, Fitzpatrick T, Ko NY, et al. Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. Lancet Glob Health. 2019 Apr;7(4):e436-47.Texto completo Resumo
74. Farley TM, Samuelson J, Grabowski MK, et al. Impact of male circumcision on risk of HIV infection in men in a changing epidemic context - systematic review and meta-analysis. J Int AIDS Soc. 2020 Jun;23(6):e25490.Texto completo Resumo
75. Delany-Moretlwe S, Gray G, Kagee A, et al. AIDS prevention in South Africa. South Afr J HIV Med. 2006;23:13-7.
76. Rubens M, Ramamoorthy V, Saxena A, et al. HIV vaccine: recent advances, current roadblocks, and future directions. J Immunol Res. 2015;2015:560347.Texto completo Resumo
77. Leal L, Lucero C, Gatell JM, et al. New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017 Jun;16(6):587-600. Resumo
78. Baden LR, Stieh DJ, Sarnecki M, et al. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020 Oct;7(10):e688-98.Texto completo Resumo
79. Gbadamosi SO, Trepka MJ, Dawit R, et al. A systematic review and meta-analysis to estimate the time from HIV infection to diagnosis for people with HIV. AIDS Rev. 2022 Mar 1;24(1):32-40.Texto completo Resumo
80. Centers for Disease Control and Prevention. Laboratory testing for the diagnosis of HIV infection: updated recommendations. Jun 2014 [internet publication].Texto completo
81. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection: United States, 2014. MMWR Recomm Rep. 2014;63(RR-03):1-10.Texto completo Resumo
82. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].Texto completo
83. World Health Organization, UNAIDS. WHO, UNAIDS statement on HIV testing services: new opportunities and ongoing challenges. Aug 2017 [internet publication].Texto completo
84. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med 2018;56(12):2015-38. Resumo
85. World Health Organization. WHO recommends HIV self-testing – evidence update and considerations for success. Nov 2019 [internet publication].Texto completo
86. World Health Organization. WHO recommends optimizing HIV testing services. Jul 2023 [internet publication].Texto completo
87. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Jul 2017 [internet publication].Texto completo
88. World Health Organization. HIV drug resistance report 2021. Nov 2021 [internet publication].Texto completo
89. Shepher J, Quinn T. Laboratory testing for HIV infection. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008:101-7.
90. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15;49(10):1582-90.Texto completo Resumo
91. Aves T, Tambe J, Siemieniuk RA, et al. Antiretroviral resistance testing in HIV-positive people. Cochrane Database Syst Rev. 2018 Nov 9;(11):CD006495.Texto completo Resumo
92. Julian T, Rekatsina M, Shafique F, et al. Human immunodeficiency virus-related peripheral neuropathy: a systematic review and meta-analysis. Eur J Neurol. 2021 Apr;28(4):1420-31. Resumo
93. Ochodo EA, Olwanda EE, Deeks JJ, et al. Point‐of‐care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities. Cochrane Database Syst Rev. 2022 Mar 10;3(3):CD013208.Texto completo Resumo
94. World Health Organization. WHO manual for HIV drug resistance testing using dried blood spot specimens. Oct 2020 [internet publication].Texto completo
95. Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. Int Health. 2021 Feb 24;13(2):98-109.Texto completo Resumo
96. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17;quiz CE1-4.Texto completo Resumo
97. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):830-2.Texto completo Resumo
98. Pitasi MA, Oraka E, Clark H, et al. HIV testing among transgender women and men - 27 states and Guam, 2014-2015. MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):883-7.Texto completo Resumo
99. Pitasi MA, Delaney KP, Oraka E, et al. Interval since last HIV test for men and women with recent risk for HIV infection - United States, 2006-2016. MMWR Morb Mortal Wkly Rep. 2018 Jun 22;67(24):677-81.Texto completo Resumo
100. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019 Jun 18;321(23):2326-36.Texto completo Resumo
101. The Voluntary HIV Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania and Trinidad: a randomised trial. Lancet. 2000 Jul 8;356(9224):103-12. Resumo
102. Smith R, Villanueva G, Probyn K, et al. Accuracy of measures for antiretroviral adherence in people living with HIV. Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD013080.Texto completo Resumo
103. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Sep 2023 [internet publication].Texto completo
104. Grobler L, Siegfried N, Visser ME, et al. Nutritional interventions for reducing morbidity and mortality in people with HIV. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004536.Texto completo Resumo
105. Olsen MF, Abdissa A, Kaestel P, et al. Effects of nutritional supplementation for HIV patients starting antiretroviral treatment: randomised controlled trial in Ethiopia. BMJ. 2014 May 15;348:g3187.Texto completo Resumo
106. Visser ME, Durao S, Sinclair D, et al. Micronutrient supplementation in adults with HIV infection. Cochrane Database Syst Rev. 2017 May 18;(5):CD003650.Texto completo Resumo
107. Teixeira NDSCCA, Pereira BM, Oliveira IKF, et al. Effect of vitamin D3 supplementation on HIV-infected adults: a systematic review. Nutr Hosp. 2019 Oct 17;36(5):1205-12.Texto completo Resumo
108. Muzembo BA, Ngatu NR, Januka K, et al. Selenium supplementation in HIV-infected individuals: A systematic review of randomized controlled trials. Clin Nutr ESPEN. 2019 Dec;34:1-7.Texto completo Resumo
109. Morvaridzadeh M, Sepidarkish M, Yavari M, et al. The effects of omega-3 fatty acid supplementation on inflammatory factors in HIV-infected patients: a systematic review and meta-analysis of randomized clinical trials. Cytokine. 2020 Dec;136:155298.Texto completo Resumo
110. US Department of Health and Human Services. HIV and immunizations. Aug 2021 [internet publication].Texto completo
111. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27;373(9):795-807.Texto completo Resumo
112. Mateo-Urdiales A, Johnson S, Smith R, et al. Rapid initiation of antiretroviral therapy for people living with HIV. Cochrane Database Syst Rev. 2019 Jun 17;(6):CD012962.Texto completo Resumo
113. Feng Q, Zhou A, Zou H, et al. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019 Jul 8;366:l4179.Texto completo Resumo
114. National Institute for Health Research. NIHR Signal: Four-drug treatment for HIV offers no benefit over standard three-drug treatment. Sep 2019 [internet publication].Texto completo
115. Cahn P, Madero JS, Arribas J, et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection - 48-week results from the GEMINI studies. Paper presented at: 22nd International AIDS Conference (AIDS 2018). 2018. Amsterdam, Netherlands.Texto completo
116. Cento V, Perno CF. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety. J Glob Antimicrob Resist. 2020 Mar;20:228-37.Texto completo Resumo
117. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Dec 2018 [internet publication].Texto completo
118. Wang H, Lu X, Yang X, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016 Oct;95(41):e5146.Texto completo Resumo
119. Tao X, Lu Y, Zhou Y, et al. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2020 Apr;93:108-17.Texto completo Resumo
120. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance. Jul 2017 [internet publication].Texto completo
121. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011 Oct 15;204(8):1217-26.Texto completo Resumo
122. El Bouzidi K, Jose S, Phillips AN, et al. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines. AIDS. 2020 Oct 1;34(12):1823-31.Texto completo Resumo
123. Lindegren ML, Kennedy CE, Bain-Brickley D, et al. Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and family planning services. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD010119.Texto completo Resumo
124. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012 Sep;13(8):453-68. Resumo
125. Segarra-Newnham M, Soffler SL. Osteoporosis and vitamin D deficiency in HIV-positive patients. J Pharm Technol. 2011;27:251-7.
126. National Institute for Health and Care Excellence. Cabotegravir with rilpivirine for treating HIV-1. Jan 2022 [internet publication].Texto completo
127. Rizzardini G, Overton ET, Orkin C, et al. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506.Texto completo Resumo
128. Chahine EB, Durham SH. Ibalizumab: the first monoclonal antibody for the treatment of HIV-1 infection. Ann Pharmacother. 2021 Feb;55(2):230-9. Resumo
129. Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018 Aug 16;379(7):645-54.Texto completo Resumo
130. Gilead Sciences. Study to evaluate the safety and efficacy of lenacapavir in combination with an optimized background regimen in heavily treatment experienced participants living with HIV-1 infection with multidrug resistance (CAPELLA). Feb 2021 [internet publication].Texto completo
131. Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023 Jan;10(1):e15-23. Resumo
132. Ogbuagu O, Segal-Maurer S, Ratanasuwan W, et al. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial. Lancet HIV. 2023 Aug;10(8):e497-e505. Resumo
133. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020 Nov;7(11):e740-51.Texto completo Resumo
134. Li L, Tian JH, Yang K, et al. Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection. Cochrane Database Syst Rev. 2014 Jul 26;(7):CD008439.Texto completo Resumo
135. Lalezari JP, Latiff GH, Brinson C, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015 Oct;2(10):e427-37. Resumo
136. Murgatroyd C, Pirrie L, Tran F, et al. Structure-activity relationships of the human immunodeficiency virus type 1 maturation inhibitor PF-46396. J Virol. 2016 Aug 26;90(18):8181-97.Texto completo Resumo
137. US National Library of Medicine. Study to evaluate the safety of a gene and cell therapy product in participants with HIV that is well-controlled on antiretroviral therapy. Sep 2020 [internet publication].Texto completo
138. Perera Molligoda Arachchige AS. NK cell-based therapies for HIV infection: investigating current advances and future possibilities. J Leukoc Biol. 2022 Apr;111(4):921-31. Resumo
139. Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023 Mar 20;S2352-3018(23)00028-0.Texto completo Resumo
140. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003 May 12;163(9):1009-21.Texto completo Resumo
141. O'Connor J, Smith C, Lampe FC, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017 Jul;4(7):e295-302.Texto completo Resumo
142. Nance RM, Delaney JAC, Simoni JM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376-84.Texto completo Resumo
143. Trickey A, McGinnis K, Gill MJ, et al. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies. Lancet HIV. 2024 Mar;11(3):e176-85.Texto completo Resumo
144. Bosh KA, Johnson AS, Hernandez AL, et al. Vital signs: deaths among persons with diagnosed HIV infection, United States, 2010-2018. MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1717-24.Texto completo Resumo
145. Teeraananchai S, Kerr SJ, Amin J, et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017 Apr;18(4):256-66. Resumo
146. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349-56.Texto completo Resumo
147. Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis. 2017 Aug 15;65(4):636-43.Texto completo
148. Ghislain MR, Mushebenge GA, Magula N. Cause of hospitalization and death in the antiretroviral era in Sub-Saharan Africa published 2008-2018: a systematic review. Medicine (Baltimore). 2021 Oct 29;100(43):e27342.Texto completo Resumo
149. Gupta RK, Peppa D, Hill AL, et al. Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV. 2020 May;7(5):e340-7.Texto completo Resumo
150. World Health Organization. First case of HIV cure in a woman after stem cell transplantation reported at CROI-2022. 2022 Mar 24 [internet publication].Texto completo
151. Mandalia S, Westrop SJ, Beck EJ, et al. Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988-2010. PLoS One. 2012;7(2):e29844.Texto completo Resumo
152. Lawn SD, Wilkinson RJ, Lipman MC, et al. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Resp Crit Care Med. 2008 Apr 1;177(7):680-5. Resumo
153. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138(11):1100-12.Texto completo Resumo
154. Losina E, Hyle EP, Borre ED, et al. Projecting 10-yr, 20-yr and lifetime risks of cardiovascular disease in persons living with HIV in the US. Clin Infect Dis. 2017 Oct 15;65(8):1266-71. Resumo
155. Beckman JA, Duncan MS, Alcorn CW, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation. 2018 Jul 17;138(3):255-65.Texto completo Resumo
156. Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018 Jun;5(6):e291-300. Resumo
157. Neesgaard B, Greenberg L, Miró JM, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV. 2022 Jul;9(7):e474-85. Resumo
158. Osibogun O, Ogunmoroti O, Michos ED, et al. HIV/HCV coinfection and the risk of cardiovascular disease: a meta-analysis. J Viral Hepat. 2017 Nov;24(11):998-1004. Resumo
159. Rao SG, Galaviz KI, Gay HC, et al. Factors associated with excess myocardial infarction risk in HIV-infected adults: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):224-30.Texto completo Resumo
160. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019 Jul 9;140(2):e98-124.Texto completo Resumo
161. Howard JFB, Rokx C, Smit C, et al. Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study. Lancet HIV. 2019 Mar;6(3):e173-81. Resumo
162. Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015 Mar 15;60(6):941-9.Texto completo Resumo
163. Adnani H, Agrawal N, Khatri A, et al. Impact of antiretroviral therapy on kidney fisease in HIV infected individuals - a qualitative systematic review. J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221089194.Texto completo Resumo
164. Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015 Dec;22(6):446-51. Resumo
165. Goh SSL, Lai PSM, Tan ATB, et al. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int. 2018 Mar;29(3):595-613.Texto completo Resumo
166. Pramukti I, Lindayani L, Chen YC, et al. Bone fracture among people living with HIV: a systematic review and meta-regression of prevalence, incidence, and risk factors. PLoS One. 2020;15(6):e0233501.Texto completo Resumo
167. Chang CJ, Chan YL, Pramukti I, et al. People with HIV infection had lower bone mineral density and increased fracture risk: a meta-analysis. Arch Osteoporos. 2021 Feb 27;16(1):47. Resumo
168. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009 Jan 2;23(1):41-50.Texto completo Resumo
169. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013 Sep;57(5):756-64.Texto completo Resumo
170. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2551-9.Texto completo Resumo
171. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015 Oct 6;163(7):507-18.Texto completo Resumo
172. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014 May 15;28(8):1181-91. Resumo
173. Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV. 2018 Nov;5(11):e647-55. Resumo
174. Park LS, Tate JP, Sigel K, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study. Ann Intern Med. 2018 Jul 17;169(2):87-96. Resumo
175. Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016;63:1160-7.Texto completo Resumo
176. Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep. 2014 Sep;11(3):317-24. Resumo
177. Wang Y, Liu M, Lu Q, et al. Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis. Neurology. 2020 Nov 10;95(19):e2610-21. Resumo
178. Eshun-Wilson I, Siegfried N, Akena DH, et al. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018 Jan 22;(1):CD008525.Texto completo Resumo
179. Monroe AK, Glesby MJ, Brown TT, et al. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015 Feb 1;60(3):453-62.Texto completo Resumo
180. Nansseu JR, Bigna JJ, Kaze AD, et al. Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Epidemiology. 2018 May;29(3):431-41.Texto completo Resumo
181. Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab Res Rev. 2017 Sep;33(6). Resumo
182. Bhatia R, Murphy AB, Raper JL, et al. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems. AIDS. 2015 Jan 2;29(1):77-81.Texto completo Resumo
183. Crothers K, Morris A. HIV infection and lung function decline: challenges, clinical implications, and new questions. AIDS. 2013 May 15;27(8):1345-7. Resumo
184. Ensink RJH, Kuper H. Is hearing impairment associated with HIV? A systematic review of data from low- and middle-income countries. Trop Med Int Health. 2017 Dec;22(12):1493-504. Resumo
185. Chokuda E, Reynolds C, Das S. Association of low vitamin D with complications of HIV and AIDS: a literature review. Infect Disord Drug Targets. 2020;20(2):122-42. Resumo
186. Brooks JT, Kawwass JF, Smith DK, et al. Effects of antiretroviral therapy to prevent HIV transmission to women in couples attempting conception when the man has HIV infection - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 18;66(32):859-60.Texto completo Resumo
187. Kawwass JF, Smith DK, Kissin DM, et al. Strategies for preventing HIV infection among HIV-uninfected women attempting conception with HIV-infected men - United States. MMWR Morb Mortal Wkly Rep. 2017 Jun 2;66(21):554-7.Texto completo Resumo
188. National Institute for Health and Care Excellence. HIV testing: increasing uptake among people who may have undiagnosed HIV. Dec 2016 [internet publication].Texto completo
189. Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):230-9. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal